Homology Medicines Key Executives
This section highlights Homology Medicines's key executives, including their titles and compensation details.
Find Contacts at Homology Medicines
(Showing 0 of )
Homology Medicines Earnings
This section highlights Homology Medicines's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
$0.93
Stock Price
$3.02M
Market Cap
42
Employees
Bedford, MA
Location
Financial Statements
Access annual & quarterly financial statements for Homology Medicines, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $1.16M | $3.21M | $33.97M | $2.70M | $1.67M |
| Cost of Revenue | $578.00K | $2.60M | $9.54M | $100.39M | $89.40M |
| Gross Profit | $578.00K | $609.00K | $24.43M | $-97.69M | $-87.73M |
| Gross Profit Ratio | 50.00% | 18.98% | 71.90% | -3615.47% | -5266.03% |
| Research and Development Expenses | $62.00M | $98.35M | $93.08M | $100.39M | $89.40M |
| General and Administrative Expenses | $31.26M | $38.14M | $36.84M | $32.57M | $22.21M |
| Selling and Marketing Expenses | $-578.00K | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $30.68M | $38.14M | $36.84M | $32.57M | $22.21M |
| Other Expenses | $9.33M | $- | $- | $- | $- |
| Operating Expenses | $92.68M | $136.49M | $129.92M | $132.97M | $111.61M |
| Cost and Expenses | $93.26M | $136.49M | $129.92M | $132.97M | $111.61M |
| Interest Income | $5.58M | $3.23M | $185.00K | $1.57M | $6.03M |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $578.00K | $-129.96M | $8.35M | $7.96M | $6.32M |
| EBITDA | $-91.52M | $-133.28M | $-87.60M | $-122.30M | $-103.62M |
| EBITDA Ratio | -7917.30% | -8205.64% | -257.86% | -4526.20% | -6219.99% |
| Operating Income | $-92.10M | $-133.28M | $-95.95M | $-130.26M | $-109.94M |
| Operating Income Ratio | -7967.30% | -4154.64% | -282.44% | -4820.98% | -6599.22% |
| Total Other Income Expenses Net | $14.35M | $134.48M | $185.00K | $1.57M | $6.03M |
| Income Before Tax | $-87.08M | $1.20M | $-95.76M | $-128.69M | $-103.92M |
| Income Before Tax Ratio | -7532.87% | 37.34% | -281.90% | -4762.92% | -6237.45% |
| Income Tax Expense | $25.88M | $715.00K | $-185.00K | $-1.57M | $-6.03M |
| Net Income | $-112.96M | $483.00K | $-95.58M | $-127.12M | $-97.89M |
| Net Income Ratio | -9771.71% | 15.06% | -281.35% | -4704.85% | -5875.69% |
| EPS | $-351.57 | $1.51 | $-311.20 | $-498.41 | $-418.35 |
| EPS Diluted | $-351.57 | $1.51 | $-311.20 | $-498.41 | $-418.35 |
| Weighted Average Shares Outstanding | 321.30K | 318.89K | 307.13K | 255.06K | 233.99K |
| Weighted Average Shares Outstanding Diluted | 321.30K | 318.89K | 307.13K | 255.06K | 233.99K |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $1.42M | $- | $354.00K | $802.00K | $802.00K | $802.00K | $802.00K | $802.00K | $802.00K | $1.68M | $2.19M | $29.30M | $980.00K | $567.00K | $567.00K | $588.00K | $563.00K | $441.00K | $392.00K |
| Cost of Revenue | $- | $1.29M | $136.00K | $564.00K | $587.00K | $633.00K | $635.00K | $786.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $- | $131.00K | $-136.00K | $-210.00K | $215.00K | $169.00K | $167.00K | $16.00K | $802.00K | $802.00K | $1.68M | $2.19M | $29.30M | $980.00K | $567.00K | $567.00K | $588.00K | $563.00K | $441.00K | $392.00K |
| Gross Profit Ratio | 0.00% | 9.20% | 0.00% | -59.30% | 26.80% | 21.10% | 20.80% | 2.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research and Development Expenses | $9.84M | $1.51M | $17.52M | $22.98M | $19.99M | $27.15M | $25.85M | $21.07M | $24.27M | $23.65M | $23.99M | $23.70M | $21.75M | $23.20M | $20.42M | $27.47M | $29.31M | $20.34M | $25.69M | $22.83M |
| General and Administrative Expenses | $5.00M | $7.90M | $6.84M | $8.19M | $8.32M | $8.15M | $7.81M | $8.03M | $14.15M | $10.78M | $8.35M | $9.04M | $8.66M | $7.59M | $8.42M | $8.79M | $7.77M | $5.78M | $6.04M | $5.54M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $5.00M | $7.90M | $6.84M | $8.19M | $8.32M | $8.15M | $7.81M | $8.03M | $14.15M | $10.78M | $8.35M | $9.04M | $8.66M | $7.59M | $8.42M | $8.79M | $7.77M | $5.78M | $6.04M | $5.54M |
| Other Expenses | $- | $2.69M | $6.64M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $14.84M | $9.41M | $31.00M | $31.17M | $28.31M | $35.30M | $33.66M | $29.11M | $38.42M | $34.43M | $32.34M | $32.74M | $30.42M | $30.78M | $28.84M | $36.26M | $37.08M | $26.12M | $31.73M | $28.36M |
| Cost and Expenses | $14.84M | $9.41M | $31.00M | $31.17M | $28.31M | $35.30M | $33.66M | $29.11M | $38.42M | $34.43M | $32.34M | $32.74M | $30.42M | $30.78M | $28.84M | $36.26M | $37.08M | $26.12M | $31.73M | $28.36M |
| Interest Income | $- | $1.18M | $1.42M | $1.51M | $1.47M | $1.46M | $1.27M | $474.00K | $32.00K | $42.00K | $53.00K | $52.00K | $38.00K | $11.00K | $41.00K | $357.00K | $1.16M | $1.39M | $1.66M | $1.70M |
| Interest Expense | $- | $1.47M | $- | $- | $- | $- | $1.27M | $474.00K | $32.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $29.00K | $43.81K | $136.00K | $217.00K | $225.00K | $296.00K | $321.00K | $328.00K | $-130.90M | $2.07M | $2.10M | $2.10M | $2.08M | $2.06M | $2.01M | $1.77M | $2.13M | $1.72M | $1.69M | $1.64M |
| EBITDA | $-14.84M | $-1.26M | $-17.59M | $-30.60M | $-27.29M | $-34.20M | $-32.23M | $-27.98M | $-37.62M | $-31.55M | $-28.56M | $-28.45M | $969.00K | $-27.75M | $-26.26M | $-33.93M | $-34.36M | $-23.84M | $-29.60M | $-26.33M |
| EBITDA Ratio | 0.00% | -663.89% | 0.00% | -8643.79% | -3402.24% | -4264.09% | -4057.48% | -3488.65% | -21012.34% | -3934.16% | -1703.16% | -1300.91% | 3.31% | -2831.22% | -4631.92% | -5983.42% | -5844.22% | -4234.46% | -6711.34% | -6717.09% |
| Operating Income | $-14.84M | $-9.41M | $-31.00M | $-30.82M | $-27.51M | $-34.49M | $-32.86M | $-28.31M | $-37.62M | $-33.62M | $-30.66M | $-30.55M | $-1.11M | $-29.80M | $-28.27M | $-35.70M | $-36.49M | $-25.56M | $-31.29M | $-27.97M |
| Operating Income Ratio | 0.00% | -663.89% | 0.00% | -8705.08% | -3430.30% | -4301.00% | -4097.51% | -3529.55% | -4690.52% | -4192.64% | -1828.32% | -1396.98% | -3.79% | -3041.02% | -4986.42% | -6295.77% | -6206.12% | -4539.79% | -7094.78% | -7135.97% |
| Total Other Income Expenses Net | $16.05M | $7.26M | $1.42M | $1.51M | $1.47M | $1.46M | $1.27M | $474.00K | $131.28M | $42.00K | $53.00K | $52.00K | $38.00K | $11.00K | $41.00K | $357.00K | $1.16M | $1.39M | $1.66M | $1.70M |
| Income Before Tax | $1.21M | $-2.15M | $-29.58M | $-29.30M | $-26.04M | $-33.04M | $-31.59M | $-27.83M | $93.66M | $-33.58M | $-30.61M | $-30.50M | $-1.07M | $-29.79M | $-28.23M | $-35.34M | $-35.33M | $-24.17M | $-29.63M | $-26.27M |
| Income Before Tax Ratio | 0.00% | -151.97% | 0.00% | -8278.25% | -3247.13% | -4119.58% | -3939.28% | -3470.45% | 11678.68% | -4187.41% | -1825.16% | -1394.60% | -3.66% | -3039.90% | -4979.19% | -6232.80% | -6008.67% | -4292.54% | -6718.14% | -6701.53% |
| Income Tax Expense | $176.00K | $13.96M | $3.38M | $5.74M | $2.80M | $-101.00K | $-46.00K | $-105.00K | $967.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Income | $1.03M | $-16.12M | $-32.95M | $-35.04M | $-28.84M | $-32.94M | $-31.55M | $-27.73M | $92.11M | $-33.58M | $-30.61M | $-30.50M | $-1.07M | $-29.79M | $-28.23M | $-35.34M | $-35.33M | $-24.17M | $-29.63M | $-26.27M |
| Net Income Ratio | 0.00% | -1136.74% | 0.00% | -9899.44% | -3596.51% | -4106.98% | -3933.54% | -3457.36% | 11484.41% | -4187.41% | -1825.16% | -1394.60% | -3.66% | -3039.90% | -4979.19% | -6232.80% | -6008.67% | -4292.54% | -6718.14% | -6701.53% |
| EPS | $1.03 | $-50.01 | $-102.53 | $-109.14 | $-89.96 | $-103.14 | $-99.34 | $-87.50 | $1.61 | $-106.01 | $-97.20 | $-97.20 | $-3.83 | $-118.57 | $-112.36 | $-140.71 | $-140.85 | $-98.95 | $-121.46 | $-109.77 |
| EPS Diluted | $0.44 | $-50.01 | $-102.53 | $-109.14 | $-89.96 | $-103.14 | $-98.85 | $-86.97 | $1.59 | $-105.85 | $-96.48 | $-97.17 | $-3.83 | $-118.57 | $-112.36 | $-140.71 | $-140.85 | $-96.34 | $-121.46 | $-109.77 |
| Weighted Average Shares Outstanding | 995.28K | 322.32K | 321.41K | 321.08K | 320.65K | 319.35K | 317.57K | 316.87K | 318.22K | 316.78K | 314.90K | 313.79K | 279.80K | 251.26K | 251.26K | 251.16K | 250.84K | 244.22K | 243.91K | 239.31K |
| Weighted Average Shares Outstanding Diluted | 2.33M | 322.32K | 321.41K | 321.08K | 320.65K | 319.35K | 319.15K | 318.81K | 321.53K | 317.26K | 317.26K | 313.87K | 279.80K | 251.26K | 251.26K | 251.16K | 250.84K | 250.84K | 243.91K | 239.31K |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $39.27M | $33.99M | $108.38M | $217.43M | $53.77M |
| Short Term Investments | $43.39M | $141.04M | $47.49M | $- | $208.61M |
| Cash and Short Term Investments | $82.65M | $175.03M | $155.87M | $217.43M | $262.39M |
| Net Receivables | $- | $- | $- | $400.00K | $400.00K |
| Inventory | $- | $- | $- | $1 | $2 |
| Other Current Assets | $1.26M | $5.99M | $36.04M | $1.73M | $3.79M |
| Total Current Assets | $83.91M | $181.01M | $191.91M | $219.56M | $266.58M |
| Property Plant Equipment Net | $650.00K | $21.64M | $17.86M | $42.90M | $42.72M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $25.81M | $1.95M | $1.27M | $1.27M |
| Tax Assets | $221.56M | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $-47.45M | $- | $- | $- |
| Total Non-Current Assets | $222.21M | $47.45M | $19.81M | $44.17M | $43.99M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $306.12M | $228.47M | $211.72M | $263.74M | $310.57M |
| Account Payables | $3.23M | $1.14M | $2.37M | $4.72M | $2.61M |
| Short Term Debt | $1.32M | $1.56M | $246.00K | $2.50M | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $1.16M | $3.21M | $5.63M | $809.00K |
| Other Current Liabilities | $7.02M | $18.71M | $11.41M | $9.80M | $8.96M |
| Total Current Liabilities | $11.57M | $22.58M | $17.23M | $22.66M | $12.37M |
| Long Term Debt | $- | $27.92M | $23.69M | $12.94M | $- |
| Deferred Revenue Non-Current | $- | $- | $1.16M | $32.14M | $30.14M |
| Deferred Tax Liabilities Non-Current | $221.56M | $- | $- | $- | $- |
| Other Non-Current Liabilities | $-221.56M | $- | $- | $- | $9.54M |
| Total Non-Current Liabilities | $221.55M | $27.92M | $24.84M | $45.08M | $39.69M |
| Other Liabilities | $1 | $- | $- | $- | $- |
| Total Liabilities | $233.13M | $50.49M | $42.07M | $67.74M | $52.06M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $6.00K | $6.00K | $6.00K | $5.00K | $4.00K |
| Retained Earnings | $-542.10M | $-429.14M | $-424.13M | $-328.37M | $-199.67M |
| Accumulated Other Comprehensive Income Loss | $-5.00K | $-404.00K | $-7.00K | $- | $183.00K |
| Other Total Stockholders Equity | $615.09M | $607.51M | $593.78M | $524.36M | $457.99M |
| Total Stockholders Equity | $72.99M | $177.98M | $169.65M | $196.00M | $258.51M |
| Total Equity | $72.99M | $177.98M | $169.65M | $196.00M | $258.51M |
| Total Liabilities and Stockholders Equity | $306.12M | $228.47M | $211.72M | $263.74M | $310.57M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $306.12M | $228.47M | $211.72M | $263.74M | $310.57M |
| Total Investments | $43.39M | $166.85M | $47.49M | $1.27M | $208.61M |
| Total Debt | $1.32M | $29.48M | $23.93M | $15.44M | $- |
| Net Debt | $-37.95M | $-4.51M | $-84.45M | $-201.99M | $-53.77M |
Balance Sheet Charts
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $115.51M | $39.27M | $29.11M | $76.80M | $39.45M | $33.99M | $43.16M | $176.19M | $248.13M | $108.38M | $95.83M | $116.31M | $104.42M | $217.43M | $178.00M | $167.64M | $143.37M | $53.77M | $77.56M | $115.57M |
| Short Term Investments | $19.80M | $43.39M | $74.19M | $50.27M | $110.57M | $141.04M | $157.91M | $49.34M | $8.00M | $47.49M | $91.72M | $96.98M | $84.23M | $- | $- | $39.01M | $91.56M | $208.61M | $192.11M | $180.23M |
| Cash and Short Term Investments | $135.31M | $82.65M | $103.30M | $127.07M | $150.03M | $175.03M | $201.07M | $225.52M | $256.13M | $155.87M | $187.55M | $213.29M | $188.65M | $217.43M | $178.00M | $206.64M | $234.93M | $262.39M | $269.67M | $295.80M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $2.73M | $1.26M | $3.34M | $4.26M | $3.56M | $5.99M | $12.13M | $12.92M | $6.32M | $36.04M | $4.27M | $4.64M | $3.00M | $2.13M | $3.25M | $3.16M | $3.40M | $4.19M | $4.41M | $2.97M |
| Total Current Assets | $138.04M | $83.91M | $106.64M | $131.34M | $153.58M | $181.01M | $213.20M | $238.44M | $262.45M | $191.91M | $191.82M | $217.94M | $191.65M | $219.56M | $181.25M | $209.81M | $238.33M | $266.58M | $274.08M | $298.77M |
| Property Plant Equipment Net | $7.82M | $650.00K | $19.47M | $20.68M | $21.26M | $21.64M | $22.32M | $16.87M | $17.59M | $17.86M | $37.73M | $39.71M | $41.77M | $42.90M | $45.83M | $47.16M | $49.18M | $42.72M | $41.41M | $41.11M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $13.96M | $17.32M | $23.04M | $25.81M | $27.13M | $29.30M | $30.64M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $221.56M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $6.47M | $- | $- | $-38.00M | $-44.30M | $-47.45M | $-49.45M | $-46.17M | $276.00K | $1.95M | $1.27M | $1.27M | $1.27M | $1.27M | $1.27M | $1.27M | $1.27M | $1.27M | $1.27M | $1.27M |
| Total Non-Current Assets | $14.29M | $222.21M | $33.43M | $38.00M | $44.30M | $47.45M | $49.45M | $46.17M | $48.51M | $19.81M | $39.00M | $40.98M | $43.05M | $44.17M | $47.11M | $48.43M | $50.45M | $43.99M | $42.68M | $42.39M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $152.33M | $306.12M | $140.06M | $169.34M | $197.88M | $228.47M | $262.65M | $284.61M | $310.96M | $211.72M | $230.82M | $258.92M | $234.70M | $263.74M | $228.36M | $258.24M | $288.79M | $310.57M | $316.76M | $341.16M |
| Account Payables | $4.96M | $3.23M | $7.80M | $3.39M | $3.63M | $1.14M | $4.83M | $3.76M | $9.88M | $2.37M | $3.52M | $5.70M | $4.88M | $4.72M | $3.32M | $7.10M | $7.40M | $2.61M | $8.80M | $8.33M |
| Short Term Debt | $3.09M | $1.32M | $1.78M | $1.70M | $1.63M | $1.56M | $1.49M | $410.00K | $435.00K | $246.00K | $1.96M | $2.14M | $2.32M | $2.50M | $2.50M | $2.41M | $2.33M | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $816.00K | $862.00K | $967.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $354.00K | $1.16M | $1.96M | $2.76M | $3.21M | $3.21M | $3.21M | $4.01M | $5.18M | $5.63M | $2.94M | $774.00K | $774.00K | $809.00K | $774.00K | $690.00K |
| Other Current Liabilities | $24.91M | $7.02M | $15.71M | $17.84M | $12.89M | $18.71M | $16.15M | $12.94M | $6.31M | $11.41M | $10.02M | $7.69M | $5.42M | $9.80M | $8.43M | $9.27M | $6.95M | $8.96M | $9.11M | $6.47M |
| Total Current Liabilities | $32.95M | $11.57M | $25.29M | $22.94M | $18.51M | $22.58M | $25.25M | $20.73M | $20.80M | $17.23M | $18.70M | $19.53M | $17.81M | $22.66M | $17.18M | $19.56M | $17.45M | $12.37M | $18.68M | $15.49M |
| Long Term Debt | $6.10M | $- | $26.56M | $27.02M | $27.48M | $27.92M | $28.34M | $23.59M | $23.55M | $23.69M | $11.58M | $12.05M | $12.50M | $12.94M | $13.54M | $14.19M | $14.82M | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $354.00K | $1.16M | $1.96M | $2.76M | $3.56M | $32.14M | $27.42M | $29.78M | $29.97M | $30.14M | $30.37M | $30.60M |
| Deferred Tax Liabilities Non-Current | $- | $221.56M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-12.94M | $-13.54M | $-14.19M | $-14.82M | $- | $- | $- |
| Other Non-Current Liabilities | $64.51M | $-221.56M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $9.54M | $9.89M | $10.33M |
| Total Non-Current Liabilities | $70.61M | $221.55M | $26.56M | $27.02M | $27.48M | $27.92M | $28.34M | $23.59M | $23.90M | $24.84M | $13.54M | $14.81M | $16.06M | $45.08M | $40.96M | $43.97M | $44.80M | $39.69M | $40.26M | $40.92M |
| Other Liabilities | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $103.56M | $233.13M | $51.85M | $49.96M | $45.98M | $50.49M | $53.59M | $44.32M | $44.70M | $42.07M | $32.24M | $34.34M | $33.87M | $67.74M | $58.14M | $63.53M | $62.25M | $52.06M | $58.94M | $56.41M |
| Preferred Stock | $152.33M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $2.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $5.00K | $5.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K |
| Retained Earnings | $-186.05M | $-542.10M | $-525.98M | $-493.02M | $-457.98M | $-429.14M | $-394.84M | $-361.12M | $-332.03M | $-424.13M | $-390.55M | $-359.94M | $-329.44M | $-328.37M | $-298.58M | $-270.35M | $-235.00M | $-199.67M | $-175.51M | $-145.88M |
| Accumulated Other Comprehensive Income Loss | $-5.00K | $-5.00K | $-36.00K | $-88.00K | $-182.00K | $-404.00K | $-457.00K | $-41.00K | $- | $-7.00K | $-5.00K | $2.00K | $-23.00K | $- | $- | $11.00K | $-19.00K | $183.00K | $254.00K | $186.00K |
| Other Total Stockholders Equity | $82.49M | $615.09M | $614.22M | $612.48M | $610.06M | $607.51M | $604.35M | $601.44M | $598.27M | $593.78M | $589.12M | $584.51M | $530.29M | $524.36M | $468.80M | $465.05M | $461.56M | $458.18M | $433.07M | $430.43M |
| Total Stockholders Equity | $48.77M | $72.99M | $88.21M | $119.38M | $151.90M | $177.98M | $209.06M | $240.29M | $266.25M | $169.65M | $198.57M | $224.58M | $200.83M | $196.00M | $170.22M | $194.70M | $226.54M | $258.51M | $257.82M | $284.74M |
| Total Equity | $48.77M | $72.99M | $88.21M | $119.38M | $151.90M | $177.98M | $209.06M | $240.29M | $266.25M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Stockholders Equity | $152.33M | $306.12M | $140.06M | $169.34M | $197.88M | $228.47M | $262.65M | $284.61M | $310.96M | $211.72M | $230.82M | $258.92M | $234.70M | $263.74M | $228.36M | $258.24M | $288.79M | $310.57M | $316.76M | $341.16M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $152.33M | $306.12M | $140.06M | $169.34M | $197.88M | $228.47M | $262.65M | $284.61M | $310.96M | $211.72M | $230.82M | $258.92M | $234.70M | $263.74M | $228.36M | $258.24M | $288.79M | $310.57M | $316.76M | $341.16M |
| Total Investments | $19.80M | $43.39M | $74.19M | $50.27M | $110.57M | $166.85M | $185.04M | $78.63M | $38.64M | $47.49M | $91.72M | $96.98M | $84.23M | $- | $- | $39.01M | $91.56M | $208.61M | $192.11M | $180.23M |
| Total Debt | $9.19M | $1.32M | $28.34M | $28.72M | $29.10M | $29.48M | $29.83M | $24.00M | $23.98M | $23.93M | $13.54M | $14.19M | $14.82M | $15.44M | $16.04M | $16.60M | $17.15M | $- | $- | $- |
| Net Debt | $-106.32M | $-37.95M | $-773.00K | $-48.07M | $-10.35M | $-4.51M | $-13.34M | $-152.19M | $-224.14M | $-84.45M | $-82.29M | $-102.12M | $-89.59M | $-201.99M | $-161.97M | $-151.03M | $-126.22M | $-53.77M | $-77.56M | $-115.57M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-112.96M | $-5.00M | $-95.76M | $-128.69M | $-103.92M |
| Depreciation and Amortization | $578.00K | $1.29M | $8.35M | $7.96M | $6.32M |
| Deferred Income Tax | $-2.09M | $- | $1.03M | $690.00K | $- |
| Stock Based Compensation | $7.32M | $13.05M | $17.25M | $13.25M | $7.63M |
| Change in Working Capital | $-7.21M | $3.35M | $-41.80M | $11.52M | $463.00K |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $2.09M | $-981.00K | $-2.49M | $2.46M | $-4.45M |
| Other Working Capital | $-9.30M | $4.33M | $-39.32M | $9.06M | $4.92M |
| Other Non Cash Items | $18.13M | $-126.35M | $1.19M | $939.00K | $-1.86M |
| Net Cash Provided by Operating Activities | $-96.23M | $-113.66M | $-109.75M | $-94.33M | $-91.36M |
| Investments in Property Plant and Equipment | $-228.00K | $-1.28M | $-2.40M | $-3.73M | $-21.83M |
| Acquisitions Net | $554.00K | $130.00M | $48.39M | $-208.63M | $29.97M |
| Purchases of Investments | $-73.24M | $-157.46M | $-97.39M | $-19.99M | $-286.39M |
| Sales Maturities of Investments | $174.24M | $65.46M | $49.00M | $228.62M | $256.43M |
| Other Investing Activities | $554.00K | $38.00M | $-48.39M | $208.63M | $-29.97M |
| Net Cash Used for Investing Activities | $101.33M | $36.72M | $-50.79M | $204.90M | $-51.80M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $184.00K | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $184.00K | $596.00K | $52.17M | $53.09M | $158.21M |
| Net Cash Used Provided by Financing Activities | $184.00K | $596.00K | $52.17M | $53.09M | $158.21M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $5.28M | $-76.35M | $-108.37M | $163.66M | $15.06M |
| Cash at End of Period | $39.27M | $33.99M | $110.33M | $218.71M | $55.05M |
| Cash at Beginning of Period | $33.99M | $110.33M | $218.71M | $55.05M | $39.99M |
| Operating Cash Flow | $-96.23M | $-113.66M | $-109.75M | $-94.33M | $-91.36M |
| Capital Expenditure | $-228.00K | $-1.28M | $-2.40M | $-3.73M | $-21.83M |
| Free Cash Flow | $-96.46M | $-114.95M | $-112.15M | $-98.06M | $-113.19M |
Cash Flow Charts
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $1.03M | $-16.12M | $-32.95M | $-35.04M | $-28.84M | $-34.30M | $-33.73M | $-29.09M | $92.11M | $-33.58M | $-30.61M | $-30.50M | $-1.07M | $-29.79M | $-28.23M | $-35.34M | $-35.33M | $-24.17M | $-29.63M | $-26.27M |
| Depreciation and Amortization | $29.00K | $- | $136.00K | $217.00K | $225.00K | $296.00K | $321.00K | $328.00K | $348.00K | $2.07M | $2.10M | $2.10M | $2.08M | $2.06M | $2.01M | $1.77M | $2.13M | $1.72M | $1.69M | $1.64M |
| Deferred Income Tax | $- | $-7.80M | $2.67M | $5.13M | $- | $- | $- | $- | $- | $357.00K | $250.00K | $252.00K | $168.00K | $887.00K | $-4.00K | $- | $- | $- | $- | $- |
| Stock Based Compensation | $417.00K | $847.00K | $1.71M | $2.40M | $2.37M | $3.09M | $2.77M | $3.14M | $4.05M | $4.66M | $4.23M | $4.47M | $3.88M | $3.57M | $3.35M | $3.45M | $2.88M | $2.44M | $1.99M | $1.97M |
| Change in Working Capital | $- | $-11.54M | $3.13M | $3.27M | $-2.07M | $3.04M | $3.99M | $-6.92M | $3.23M | $-4.26M | $-1.65M | $-727.00K | $-35.16M | $11.42M | $-6.24M | $1.70M | $4.65M | $-6.06M | $867.00K | $1.53M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $928.00K | $-4.57M | $4.41M | $-242.00K | $2.49M | $-3.69M | $1.07M | $-6.06M | $7.70M | $-1.36M | $-2.11M | $1.09M | $-100.00K | $1.97M | $-4.43M | $79.00K | $4.84M | $-5.96M | $935.00K | $661.00K |
| Other Working Capital | $- | $-6.97M | $-1.28M | $3.51M | $-4.56M | $6.74M | $2.92M | $-854.00K | $-4.47M | $-2.90M | $460.00K | $-1.82M | $-35.06M | $9.44M | $-1.81M | $1.62M | $-192.00K | $-101.00K | $-68.00K | $866.00K |
| Other Non Cash Items | $- | $5.24M | $365.00K | $364.00K | $2.27M | $668.00K | $1.71M | $1.69M | $-130.42M | $322.00K | $300.00K | $290.00K | $279.00K | $253.00K | $236.00K | $432.00K | $-175.00K | $-257.00K | $-401.00K | $-539.00K |
| Net Cash Provided by Operating Activities | $-14.55M | $-21.57M | $-24.94M | $-23.66M | $-26.05M | $-27.20M | $-24.93M | $-30.85M | $-30.68M | $-30.43M | $-25.39M | $-24.11M | $-29.82M | $-11.61M | $-28.89M | $-27.99M | $-25.85M | $-26.33M | $-25.48M | $-21.67M |
| Investments in Property Plant and Equipment | $- | $338.00K | $-338.00K | $- | $-228.00K | $-9.00K | $-6.00K | $-121.00K | $-1.15M | $-338.00K | $-477.00K | $-764.00K | $-817.00K | $-955.00K | $-157.00K | $-588.00K | $-2.03M | $-3.73M | $-1.72M | $-5.92M |
| Acquisitions Net | $- | $216.00K | $338.00K | $- | $-31.60M | $-130.00M | $- | $- | $130.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $-47.96M | $1.00K | $-25.28M | $- | $-108.21M | $-49.25M | $-130.00M | $-1.00K | $1.00K | $-12.97M | $-84.42M | $64.52K | $1.00K | $-19.99M | $- | $-29.00M | $-67.91M | $-105.01M |
| Sales Maturities of Investments | $97.00K | $31.50M | $24.86M | $61.00M | $56.88M | $18.00M | $- | $8.00M | $39.46M | $44.00M | $5.00M | $- | $- | $- | $39.00M | $72.59M | $117.03M | $12.70M | $56.50M | $72.62M |
| Other Investing Activities | $- | $-31.38M | $338.00K | $61.00M | $31.60M | $130.00M | $-108.21M | $-41.25M | $130.00M | $- | $- | $- | $- | $-64.52K | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $97.00K | $31.72M | $-22.76M | $61.00M | $31.37M | $17.99M | $-108.22M | $-41.37M | $168.31M | $43.66M | $4.52M | $-13.74M | $-85.23M | $-955.00K | $38.84M | $52.01M | $115.00M | $-20.03M | $-13.14M | $-38.30M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $42.00M | $14.00K | $18.00K | $2.00K | $150.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $99.35M | $14.00K | $18.00K | $2.00K | $150.00K | $32.00K | $124.00K | $- | $440.00K | $1.00K | $379.00K | $49.75M | $2.04M | $51.99M | $410.00K | $241.00K | $447.00K | $22.57M | $614.00K | $134.70M |
| Net Cash Used Provided by Financing Activities | $99.35M | $14.00K | $18.00K | $2.00K | $150.00K | $32.00K | $124.00K | $- | $440.00K | $1.00K | $379.00K | $49.75M | $2.04M | $51.99M | $410.00K | $241.00K | $447.00K | $22.57M | $614.00K | $134.70M |
| Effect of Forex Changes on Cash | $- | $-14.73M | $14.73M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $84.89M | $10.15M | $-47.69M | $37.34M | $5.47M | $-9.18M | $-133.03M | $-72.22M | $138.07M | $13.23M | $-20.48M | $11.90M | $-113.02M | $39.43M | $10.37M | $24.26M | $89.60M | $-23.79M | $-38.01M | $74.73M |
| Cash at End of Period | $116.16M | $39.27M | $29.11M | $76.80M | $39.45M | $33.99M | $43.16M | $176.19M | $248.40M | $110.33M | $97.10M | $117.59M | $105.69M | $218.71M | $179.28M | $168.91M | $144.65M | $55.05M | $78.83M | $116.84M |
| Cash at Beginning of Period | $31.26M | $29.11M | $76.80M | $39.45M | $33.99M | $43.16M | $176.19M | $248.40M | $110.33M | $97.10M | $117.59M | $105.69M | $218.71M | $179.28M | $168.91M | $144.65M | $55.05M | $78.83M | $116.84M | $42.11M |
| Operating Cash Flow | $-14.55M | $-21.57M | $-24.94M | $-23.66M | $-26.05M | $-27.20M | $-24.93M | $-30.85M | $-30.68M | $-30.43M | $-25.39M | $-24.11M | $-29.82M | $-11.61M | $-28.89M | $-27.99M | $-25.85M | $-26.33M | $-25.48M | $-21.67M |
| Capital Expenditure | $- | $338.00K | $-338.00K | $- | $-228.00K | $-9.00K | $-6.00K | $-121.00K | $-1.15M | $-338.00K | $-477.00K | $-764.00K | $-817.00K | $-955.00K | $-157.00K | $-588.00K | $-2.03M | $-3.73M | $-1.72M | $-5.92M |
| Free Cash Flow | $-14.55M | $-21.24M | $-25.28M | $-23.66M | $-26.28M | $-27.21M | $-24.94M | $-30.97M | $-31.83M | $-30.77M | $-25.86M | $-24.88M | $-30.64M | $-12.57M | $-29.04M | $-28.57M | $-27.88M | $-30.06M | $-27.21M | $-27.59M |
Homology Medicines Dividends
Explore Homology Medicines's dividend history, including dividend yield, payout ratio, and historical payments.
Homology Medicines News
Read the latest news about Homology Medicines, including recent articles, headlines, and updates.
Homology Medicines Declares Distribution to Common Stockholders
BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstanding share of Homology common stock held by such stockholder as of such record date. The payment date for such distribution is expected to be March 27, 2024 (three business days after the expected closing of the merger on March 22, 2024). Each CVR represents the non-transferable contractual right to receive certain contingent payments upon the occurrence of certain events within agreed time periods as provided in the merger agreement and agreement governing the CVRs.
HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Homology Medicines, Inc. (NasdaqGS: FIXX) with Q32 Bio Inc. Under the terms of the proposed transaction, Homology shareholders will end up owning approximately 25% of the combined company, subject to possible adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequa.
FIXX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Homology Medicines, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Homology Medicines, Inc. (NASDAQ: FIXX) and Q32 Bio Inc. is fair to Homology shareholders. Upon completion of the proposed transaction, Homology shareholders are expected to own approximately 25% of the combined company. Halper Sadeh encourages Homology shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763.
Q32 Bio and Homology Medicines Announce Merger Agreement
--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio's two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders-- --Q32 Bio has re-acquired worldwide development and commercial rights to bempikibart, an anti-IL-7Rα antibody inhibiting IL-7 and TSLP-mediated signaling, and remains on-track to report multiple topline Phase 2 results in 2H'24 -- --Concurrent $42 million private placement investment with new and existing investors supports clinical development through multiple milestones, including key Phase 2 readouts for bempikibart, initial ADX-097 proof-of-concept data by year-end 2024 and ADX-097 topline results in 2H'25 -- --Combined company's cash balance expected to be approximately $ 115 million at close, providing cash runway to mid-2026-- WALTHAM, Mass. and BEDFORD, Mass.
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. (NASDAQ: FIXX) and Encourages Long-Term Investors to Contact the Firm - FIXX
PHILADELPHIA , Aug. 16, 2023 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) on behalf of the Company's long-term investors. Recently an amended securities fraud complaint was filed against Homology on behalf of investors who purchased shares of the Company's stock between March 12, 2020 and February 18, 2022.
Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU
Participant 1 Achieved Clinically Meaningful Reduction in Plasma Phe of Up to 99% Change from Baseline and Below the U.S. PKU Treatment Guideline Threshold (
Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU
BEDFORD, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following conferences:
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Homology Medicines, Inc. (FIXX) Shareholders of Class Action Last Few Hours to Actively Participate
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) and certain of its officers, on behalf of all persons and entities that purchased or otherwise acquired Homology securities between June 10, 2019 and February 18, 2022, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/fixx. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws. The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company had overstated HMI-102's efficacy and risk mitigation; (2) accordingly, it was unlikely that the Company would be able to commercialize HMI-102 in its present form; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times. A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/fixx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Homology you have until May 24, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
HOMOLOGY DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Homology Medicines, Inc. and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired Homology securities between June 10, 2019 and February 18, 2022, both dates inclusive (the “Class Period”). Investors have until May 24, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. Homology, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. The Company's lead product candidate is HMI-102, which is in Phase I/II pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults (the "HMI-102 Trial"). On June 10, 2019, Homology issued a press release announcing that it had commenced enrollment of the HMI-102 Trial. The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company had overstated HMI-102's efficacy and risk mitigation; (ii) accordingly, it was unlikely that the Company would be able to commercialize HMI-102 in its present form; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times. On July 21, 2020, Mariner Research ("Mariner") published a report questioning statements by Homology and its officers about the efficacy of HMI-102, the Company's lead product candidate for treatment of phenylketonuria. Mariner focused on Homology's HMI-102 dose escalation pheNIX trial, concluding that the Company concealed data showing HMI-102's lack of efficacy and indicating that the program was unlikely to proceed to commercialization. Among other evidence, Mariner cited an email from Homology's Chief Communications Officer appearing to indicate the Company's awareness that a HMI-102 high dose patient had adverted to the adverse efficacy issue in a social media post during April 2020. On this news, Homology's stock price fell $1.71 per share, or 10.38%, over the following three trading days, closing at $14.77 per share on July 24, 2020. Then, on February 18, 2022, Homology issued a press release disclosing that "the U.S. Food and Drug Administration has notified the company that its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria has been placed on clinical hold due to the need to modify risk mitigation measures in the study in response to observations of elevated liver function tests" and that "[t]he Company expects to receive an official clinical hold letter within 30 days." On this news, Homology's stock price fell $1.26 per share, or 32.64%, to close at $2.60 per share on February 22, 2022. If you purchased or otherwise acquired Homology shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
FIXX Stock News: Robbins LLP Investigates Homology Medicines, Inc. (FIXX) for Shareholders
SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Homology Sciences, Inc. (NASDAQ: FIXX) and its officers and directors to determine whether they breached their fiduciary duties and violated securities laws in relation to the misstatements concerning its lead drug candidate HMI-102. Homology is a genetic medicines company that focuses on transforming the lives of patients suffering from rare genetic diseases. The Company's lead product candidate is HMI-102, a gene therapy for the treatment of phenylketonuria (PKU) in adults. If you would like more information about our investigation of Homology Medicines, Inc.'s misconduct, click here. What is this Case About: According to a complaint filed against Homology, defendants touted the progress of the Company's HMI-102 trial and the efficacy of the therapy. However, these statements were false. Defendants failed to disclose that the Company had overstated HMI-102's efficacy and risk mitigation, and therefore, it was unlikely the Company would be able to commercialize HMI-102 in its present form. On February 18, 2022, Homology issued a press release disclosing that “the U.S. Food and Drug Administration (FDA) has notified the company that its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria (PKU) has been placed on clinical hold due to the need to modify risk mitigation measures in the study in response to observations of elevated liver function tests” and that “[t]he Company expects to receive an official clinical hold letter within 30 days.” On this news, Homology’s stock price fell $1.26 per share, or 32.64%, to close at $2.60 per share on February 22, 2022. Next Steps: If you acquired shares of Homology Medicines, Inc. (FIXX) between June 10, 2019 and February 18, 2022, you have legal options. Contact Robbins LLP for more information. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. Contact us to learn more: Aaron Dumas (800) 350-6003 adumas@robbinsllp.com Shareholder Information Form About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Homology Medicines, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
全球投資人法律顧問ROSEN鼓勵蒙受損失的Homology Medicines, Inc.投資人在FIXX證券集體訴訟的重要截止日期前聘請律師
紐約--(BUSINESS WIRE)--(美國商業資訊)--原因：全球投資人權益法律事務所Rosen Law Firm提醒在2019年6月10日至2022年2月18日期間（含上述日期，簡稱「集體訴訟期」）購買Homology Medicines, Inc. (NASDAQ: FIXX)證券的人士牢記，原告代表的截止日期為2022年5月24日。 這意味著什麼：在集體訴訟期購買了Homology證券的人士，可能有機會透過勝訴分成安排而獲得賠償，無需支付任何自付費用或成本。 接下來該如何做：如欲加入Homology集體訴訟，請造訪https://rosenlegal.com/submit-form/?case_id=4851、致電免費電話866-767-3653，或者寄送電子郵件至pkim@rosenlegal.com或cases@rosenlegal.com，與Phillip Kim律師連絡，瞭解有關集體訴訟的更多資訊。法律事務所已經提起了集體訴訟案。如果您希望擔任原告代表，則必須在2022年5月24日之前向法院提出申請。原告代表是代表其他集體成員主導訴訟的代表方。 為什麼選擇ROSEN LAW：我們鼓勵投資人選擇合格且在擔任領導職務方面有成功可查記錄的律師。通常，發佈通知的法律事務所並無可相比的經驗、資源或任何有意義的同儕認可。許多此類法律事務所實際上並不處理證券集體訴訟，而只是充當中間人，把客戶介紹給真正提起訴訟的法律事務所，或與真正提起訴訟的事務所合作。請務必明智選擇法律顧問。Rosen Law Firm在全球為投資人提供服務，專注於證券集體訴訟和股東派生訴訟。Rosen Law Firm曾針對一家中國公司發起了迄今規模最大的證券集體訴訟，並成功達成和解。2017年，Rosen Law Firm曾因其證券集體訴訟和解數量，而被ISS Securities Class Action Services評選為排名第一的法律事務所。自2013年以來，Rosen Law Firm每年都進入該排行榜的前四名，而且已為投資人追回數億美元的資金。事務所僅在2019年便為投資人追回了超過4.38億美元的資金。2020年，創始合夥人Laurence Rosen被law360評選為「最佳原告律師」(Titan of Plaintiffs’ Bar)。事務所的眾多律師都得到Lawdragon和Super Lawyers的表揚。 案件詳情：本訴訟認為，被告在整個集體訴訟期間做出虛假和/或誤導性陳述和/或未揭露：(1) Homology誇大了HMI-102的療效和風險減輕作用，HMI-102是治療成人苯丙酮尿症(PKU)的基因療法，處於第I/II期pheNIX臨床試驗階段；(2)因此，Homology不太可能以目前的形式將HMI-102商業化；以及(3)因此，被告在所有相關時間的公開陳述都存在重大虛假和誤導性。訴訟稱，當市場瞭解真實資訊之後，投資人便蒙受了損失。 如欲加入Homology集體訴訟，請造訪https://rosenlegal.com/submit-form/?case_id=4851、致電免費電話866-767-3653，或者寄送電子郵件至pkim@rosenlegal.com或cases@rosenlegal.com，與Phillip Kim律師連絡，瞭解有關集體訴訟的更多資訊。 上述訴訟的集體尚未得到認證。在此之前，除受聘之外，律師將不會為個人提供法律服務。個人可自行選擇聘請律師，也可以作為缺席集體訴訟成員，且目前無需採取任何行動。投資人在未來任何可能的賠償中的分成金額與其是否為原告代表無關。 敬請在LinkedIn：https://www.linkedin.com/company/the-rosen-law-firm、Twitter：https://twitter.com/rosen_firm或Facebook：https://www.facebook.com/rosenlawfirm/關注我們，瞭解最新情況。 律師廣告。先前的結果並不保證可獲致類似結果。 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
全球投资者法律顾问ROSEN鼓励蒙受损失的Homology Medicines, Inc.投资者在FIXX证券集体诉讼的重要截止日期前聘请律师
纽约--(BUSINESS WIRE)--(美国商业资讯)--原因：全球投资者权益律师事务所Rosen Law Firm提醒在2019年6月10日至2022年2月18日期间（含上述日期，简称“集体诉讼期”）购买Homology Medicines, Inc. (NASDAQ: FIXX)证券的人士牢记，首席原告的截止日期为2022年5月24日。 这意味着什么：在集体诉讼期购买了Homology证券的人士，可以通过风险代理费安排，有机会无需支付任何自付费用和花销而获得赔偿。 接下来该如何做：如需加入Homology集体诉讼，请访问https://rosenlegal.com/submit-form/?case_id=4851、拨打免费电话866-767-3653或者发送电子邮件至pkim@rosenlegal.com或cases@rosenlegal.com联系Phillip Kim律师，了解有关集体诉讼的更多信息。律所已经提起了集体诉讼案。如果您希望担任首席原告，则必须在2022年5月24日之前向法院提出申请。首席原告是代表其他集体成员主导诉讼的代表方。 为什么选择ROSEN LAW：我们鼓励投资者选择有资质且在担任领导职务方面有着成功可查记录的律师。通常，发布通知的律所并无可相比的经验、资源或任何严谨的同行认可。许多此类律所实际上并不从事证券集体诉讼，只是充当中间人，将客户介绍给真正提起诉讼的律所，或与真正提起诉讼的律所合作。请务必明智选择法律顾问。Rosen Law Firm在全球范围内为投资者提供服务，专注于证券集体诉讼和股东派生诉讼。Rosen Law Firm曾针对一家中国公司发起了迄今规模最大的证券集体诉讼，并成功达成了和解。Rosen Law Firm曾因其证券集体诉讼和解数量，于2017年被ISS Securities Class Action Services评选为排名第一的律所。自2013年以来，Rosen Law Firm每年都进入了该榜单的前四强，而且为投资者追回了数亿美元的资金。律所仅在2019年便为投资者追回了超过4.38亿美元的资金。2020年，创始合伙人Laurence Rosen被law360评选为“最佳原告律师”(Titan of Plaintiffs’ Bar)。律所的众多律师都得到了Lawdragon和Super Lawyers的表彰。 案件详情：本诉讼认为，被告在整个集体诉讼期间做出了虚假和/或误导性陈述和/或未披露：(1) Homology夸大了HMI-102的疗效和风险缓解作用，HMI-102是一种治疗成人苯丙酮尿症(PKU)的基因疗法，处于I/II期pheNIX临床试验阶段；(2)因此，Homology不太可能以目前的形式将HMI-102商业化；以及(3)因此，被告在所有相关时间的公开陈述都存在重大虚假和误导性。诉讼称，当市场了解真实信息之后，投资者便蒙受了损失。 如需加入Homology集体诉讼，请访问https://rosenlegal.com/submit-form/?case_id=4851、拨打免费电话866-767-3653或者发送电子邮件至pkim@rosenlegal.com或cases@rosenlegal.com联系Phillip Kim律师，了解有关集体诉讼的更多信息。 上述诉讼的集体尚未得到认证。在此之前，除受聘之外，律师将不会为个人提供法律服务。个人可自行选择聘请律师，也可以作为缺席集体诉讼成员，且目前无需采取任何行动。投资者在未来任何可能的赔偿中的分成金额大小与其是否作为首席原告无关。 敬请通过LinkedIn：https://www.linkedin.com/company/the-rosen-law-firm、Twitter：https://twitter.com/rosen_firm或Facebook：https://www.facebook.com/rosenlawfirm/关注我们，了解最新情况。 律师广告。先前的结果并不保证可实现类似结果。 免责声明：本公告之原文版本乃官方授权版本。译文仅供方便了解之用，烦请参照原文，原文版本乃唯一具法律效力之版本。
HOMOLOGY DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Homology Medicines, Inc. and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired Homology securities between June 10, 2019 and February 18, 2022, both dates inclusive (the “Class Period”). Investors have until May 24, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. Homology, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. The Company's lead product candidate is HMI-102, which is in Phase I/II pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults (the "HMI-102 Trial"). On June 10, 2019, Homology issued a press release announcing that it had commenced enrollment of the HMI-102 Trial. The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company had overstated HMI-102's efficacy and risk mitigation; (ii) accordingly, it was unlikely that the Company would be able to commercialize HMI-102 in its present form; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times. On July 21, 2020, Mariner Research ("Mariner") published a report questioning statements by Homology and its officers about the efficacy of HMI-102, the Company's lead product candidate for treatment of phenylketonuria. Mariner focused on Homology's HMI-102 dose escalation pheNIX trial, concluding that the Company concealed data showing HMI-102's lack of efficacy and indicating that the program was unlikely to proceed to commercialization. Among other evidence, Mariner cited an email from Homology's Chief Communications Officer appearing to indicate the Company's awareness that a HMI-102 high dose patient had adverted to the adverse efficacy issue in a social media post during April 2020. On this news, Homology's stock price fell $1.71 per share, or 10.38%, over the following three trading days, closing at $14.77 per share on July 24, 2020. Then, on February 18, 2022, Homology issued a press release disclosing that "the U.S. Food and Drug Administration has notified the company that its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria has been placed on clinical hold due to the need to modify risk mitigation measures in the study in response to observations of elevated liver function tests" and that "[t]he Company expects to receive an official clinical hold letter within 30 days." On this news, Homology's stock price fell $1.26 per share, or 32.64%, to close at $2.60 per share on February 22, 2022. If you purchased or otherwise acquired Homology shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Homology Medicines, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – FIXX
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”), of the important May 24, 2022 lead plaintiff deadline. SO WHAT: If you purchased Homology securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Homology class action, go to https://rosenlegal.com/submit-form/?case_id=4851 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 24, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Homology had overstated the efficacy and risk mitigation regarding HMI-102, which is in Phase I/II pheNIX clinical trial and a gene therapy for the treatment of phenylketonuria (PKU) in adults; (2) accordingly, it was unlikely that Homology would be able to commercialize HMI-102 in its present form; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Homology class action, go to https://rosenlegal.com/submit-form/?case_id=4851 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome.
HOMOLOGY ALERT: Bragar Eagel & Squire, P.C. is Investigating Homology Medicines, Inc. on Behalf of Homology Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of Homology stockholders. Our investigation concerns whether Homology has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Homology had overstated the efficacy and risk mitigation regarding HMI-102, which is in Phase I/II pheNIX clinical trial and a gene therapy for the treatment of phenylketonuria (PKU) in adults; (2) accordingly, it was unlikely that Homology would be able to commercialize HMI-102 in its present form; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, Homology's stock price fell $1.26 per share, or 32.64%, to close at $2.60 per share on February 22, 2022. If you purchased or otherwise acquired Homology shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
FIXX ALERT: Investors with Substantial Losses Have Opportunity to Lead Homology Medicines, Inc. Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that purchasers of Homology Medicines, Inc. (NASDAQ: FIXX) securities between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”) have until May 24, 2022 to seek appointment as lead plaintiff in Pizzuto v. Homology Medicines, Inc., No. 22-cv-01968 (C.D. Cal.). Commenced on March 25, 2022 and assigned to Judge Fernando L. Aenlle-Rocha, the Homology Medicines class action lawsuit charges Homology Medicines as well as certain of its top executive officers with violations of the Securities Exchange Act of 1934. If you suffered significant losses and wish to serve as lead plaintiff of the Homology Medicines class action lawsuit, please provide your information by clicking here. You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com. Lead plaintiff motions for the Homology Medicines class action lawsuit must be filed with the court no later than May 24, 2022. CASE ALLEGATIONS: Homology Medicines is a genetic medicines company and its lead product candidate is HMI-102, a gene therapy for the treatment of phenylketonuria (“PKU”) in adults that is in Phase I/II pheNIX clinical trial (the “HMI-102 Trial”). On June 10, 2019, Homology Medicines issued a press release announcing that it had commenced enrollment of the HMI-102 Trial. The Homology Medicines class action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) Homology Medicines had overstated HMI-102’s efficacy and risk mitigation; (ii) accordingly, it was unlikely that Homology Medicines would be able to commercialize HMI-102 in its present form; and (iii) as a result, Homology Medicines’ public statements were materially false and misleading at all relevant times. On July 21, 2020, Mariner Research published a report questioning statements by Homology Medicines and its officers about the efficacy of HMI-102. Mariner focused on Homology Medicines’ HMI-102 dose escalation pheNIX trial, concluding that Homology Medicines concealed data showing HMI-102’s lack of efficacy and indicating that the program was unlikely to proceed to commercialization. Among other evidence, Mariner cited an email from Homology Medicines’ Chief Communications Officer appearing to indicate Homology Medicines’ awareness that a HMI-102 high dose patient had adverted to the adverse efficacy issue in a social media post during April 2020. On this news, Homology Medicines’ stock price fell by more than 10%. Then, on February 18, 2022, Homology Medicines disclosed that “the U.S. Food and Drug Administration (FDA) has notified the company that its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria (PKU) has been placed on clinical hold due to the need to modify risk mitigation measures in the study in response to observations of elevated liver function tests” and that Homology Medicines “expects to receive an official clinical hold letter within 30 days.” On this news, Homology Medicines’ stock price fell by more than 32%, further damaging investors. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Homology Medicines securities during the Class Period to seek appointment as lead plaintiff in the Homology Medicines class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the class action lawsuit. An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff. ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: Robbins Geller Rudman & Dowd LLP is one of the world’s leading complex class action firms representing plaintiffs in securities fraud cases. The Firm is ranked #1 on the 2021 ISS Securities Class Action Services Top 50 Report for recovering nearly $2 billion for investors last year alone – more than triple the amount recovered by any other plaintiffs’ firm. With 200 lawyers in 9 offices, Robbins Geller’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit http://www.rgrdlaw.com for more information. Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. https://www.linkedin.com/company/rgrdlaw https://twitter.com/rgrdlaw https://www.facebook.com/rgrdlaw
Bronstein, Gewirtz & Grossman, LLC Notifies Homology Medicines, Inc. (FIXX) Shareholders of Class Action and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) and certain of its officers, on behalf of all persons and entities that purchased or otherwise acquired Homology securities between June 10, 2019 and February 18, 2022, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/fixx. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws. The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company had overstated HMI-102's efficacy and risk mitigation; (2) accordingly, it was unlikely that the Company would be able to commercialize HMI-102 in its present form; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times. A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/fixx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Homology you have until May 24, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
FIXX Shareholder Class Action: Robbins LLP Reminds Investors of Class Action Against Homology Medicines, Inc. (FIXX)
SAN DIEGO--(BUSINESS WIRE)--The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Homology Sciences, Inc. (NASDAQ: FIXX) securities between June 10, 2019 and February 18, 2022, for violations of the Securities Exchange Act of 1934. Homology is a genetic medicines company that focuses on transforming the lives of patients suffering from rare genetic diseases. The Company's lead product candidate is HMI-102, a gene therapy for the treatment of phenylketonuria (PKU) in adults. If you would like more information about Homology Medicines, Inc.'s misconduct, click here. What is this Case About: Homology Medicines, Inc. (FIXX) Misled the Investing Public Regarding its Lead Drug Candidate HMI-102 According to the complaint, on June 10, 2019, Homology announced it had commenced enrollment of the HMI-102 Trial. Throughout the class period, defendants touted the progress of the trial and the efficacy of the therapy. However, these statements were false. Defendants failed to disclose that the Company had overstated HMI-102's efficacy and risk mitigation, and therefore, it was unlikely the Company would be able to commercialize HMI-102 in its present form. On February 18, 2022, Homology issued a press release disclosing that “the U.S. Food and Drug Administration (FDA) has notified the company that its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria (PKU) has been placed on clinical hold due to the need to modify risk mitigation measures in the study in response to observations of elevated liver function tests” and that “[t]he Company expects to receive an official clinical hold letter within 30 days.” On this news, Homology’s stock price fell $1.26 per share, or 32.64%, to close at $2.60 per share on February 22, 2022. Next Steps: If you acquired shares of Homology Medicines, Inc. (FIXX) between June 10, 2019 and February 18, 2022, you have until May 24, 2022, to ask the court to appoint you lead plaintiff for the class. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. Contact us to learn more: Aaron Dumas (800) 350-6003 adumas@robbinsllp.com Shareholder Information Form About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Homology Medicines, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for FIXX.